Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status

doi:doi.org/10.1097/MD.0000000000017692

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/22459

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/22459

Title:	Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status
Authors:	Lee, Shou-Wu;Lee, Teng-Yu;Peng, Yen-Chun;Yang, Sheng-Shun;Yeh, Hong-Zen;Chang, Chi-Sen
Date:	2019-11
Issue Date:	2022-06-27T03:35:08Z (UTC)
Publisher:	Wolters Kluwer Health
Abstract:	Sorafenib is of proven efficacy in treating patients of hepatocellular carcinoma (HCC). Our study was aimed to determine the factors influence the sorafenib efficacy. We evaluated data of HCC patients receiving sorafenib from June 2012 to October 2016. All HCC cases were of the Barcelona Clinic Liver Cancer (BCLC) classification stage C. The exclusion criteria: those of BCLC classification stage A or B, with the absence or co-infection of hepatitis B (HBV) and hepatitis C (HCV). The presence of HBV, HCV, macoscopic vascular invasion (MVI) or extrahepatic spread (EHS) was recorded for each patient. Time-to-progression (TTP) and overall survival (OS) were analyzed. Among a total of 90 HCC patients, 48 (53.3%) had HBV infection, 42 (46.7%) had HCV infection, 51 (56.7%) had MVI, and 39 (43.3%) had EHS. Patients with HCV infection showed better TTP and OS than those with HBV infection. Patients with EHS had a longer TTP and OS than those with MVI. For patients with HBV infection, those with EHS had a longer TTP (mean 4.60 vs 2.64 months, P = .002) and OS (mean 6.65 vs 4.53 months, P = .045) compared to those with MVI. Among those with MVI, patients with HBV infection had a poorer TTP (mean 2.64 vs 4.74 months, P = .019) and shorter OS (mean 4.53 vs 7.00 months, P = .059) compared to those with HCV infection. HCC patients with HCV infection or with the presence of EHS showed better sorafenib efficacy.
URI:	https://ir.csmu.edu.tw:8080/handle/310902500/22459
Relation:	Medicine: November 2019 - Volume 98 - Issue 44 - p e17692
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

File	Description	Size	Format
Sorafenib_treatment_on_Chinese_patients_with.54.pdf		387Kb	Adobe PDF	240	View/Open

View Licence

Loading...